OTCM
EPTMF
Market cap28mUSD
Oct 15, Last price
0.99USD
Name
Epitomee Medical Ltd
Chart & performance
P/E
—
P/S
40.61
EPS
—
Div yield, %
—
Shrs. gr., 5y
0.41%
Rev. gr., 5y
%
Revenues
735k
Net income
-30m
L+457.85%
CFO
-24m
L-19.78%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Epitomee Medical Ltd develops and commercializes ingestible therapeutic devices in Israel. The company offers capsules for the treatment of overweight and obesity. It also focuses on developing biologic drug delivery solutions. Epitomee Medical Ltd was incorporated in 2005 and is based in Caesarea, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||